Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 185

1.

Frailty in multiple myeloma: the need for harmony to prevent doing harm.

Zweegman S, Larocca A.

Lancet Haematol. 2019 Mar;6(3):e117-e118. doi: 10.1016/S2352-3026(19)30011-0. Epub 2019 Feb 6. No abstract available.

2.

Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A Consensus Paper by the European Myeloma Network and the Italian Society of Arterial Hypertension.

Bringhen S, Milan A, D'Agostino M, Ferri C, Wäsch R, Gay F, Larocca A, Offidani M, Zweegman S, Terpos E, Goldschmidt H, Cavo M, Ludwig H, Driessen C, Auner H, Caers J, Gramatzki M, Dimopoulos MA, Boccadoro M, Einsele H, Sonneveld P, Engelhardt M.

J Intern Med. 2019 Feb 6. doi: 10.1111/joim.12882. [Epub ahead of print]

PMID:
30725503
3.

Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation - A Network Meta-analysis.

Blommestein HM, van Beurden-Tan CHY, Franken MG, Uyl-de Groot CA, Sonneveld P, Zweegman S.

Haematologica. 2019 Jan 3. pii: haematol.2018.206912. doi: 10.3324/haematol.2018.206912. [Epub ahead of print]

4.

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.

Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group.

Lancet. 2019 Jan 19;393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4. Epub 2018 Dec 10.

PMID:
30545780
5.

IGFBP7 Induces Differentiation and Loss of Survival of Human Acute Myeloid Leukemia Stem Cells without Affecting Normal Hematopoiesis.

Verhagen HJMP, van Gils N, Martiañez T, van Rhenen A, Rutten A, Denkers F, de Leeuw DC, Smit MA, Tsui ML, de Vos Klootwijk LLE, Menezes RX, Çil M, Roemer MGM, Vermue E, Heukelom S, Zweegman S, Janssen JJWM, Ossenkoppele GJ, Schuurhuis GJ, Smit L.

Cell Rep. 2018 Dec 11;25(11):3021-3035.e5. doi: 10.1016/j.celrep.2018.11.062.

6.

Ixazomib for the treatment of multiple myeloma.

Richardson PG, Zweegman S, O'Donnell EK, Laubach JP, Raje N, Voorhees P, Ferrari RH, Skacel T, Kumar SK, Lonial S.

Expert Opin Pharmacother. 2018 Dec;19(17):1949-1968. doi: 10.1080/14656566.2018.1528229. Epub 2018 Nov 13. Review.

PMID:
30422008
7.

Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment.

Frerichs KA, Bosman PWC, Nijhof IS, Zweegman S, van de Donk NWCJ.

Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):e9-e11. doi: 10.1016/j.clml.2018.10.002. Epub 2018 Oct 13. No abstract available.

PMID:
30392824
8.

Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients.

Franssen LE, Nijhof IS, Bjorklund CC, Chiu H, Doorn R, van Velzen J, Emmelot M, van Kessel B, Levin MD, Bos GMJ, Broijl A, Klein SK, Koene HR, Bloem AC, Beeker A, Faber LM, van der Spek E, Raymakers R, Sonneveld P, Zweegman S, Lokhorst HM, Thakurta A, Qian X, Mutis T, van de Donk NWCJ.

Oncotarget. 2018 Sep 21;9(74):34009-34021. doi: 10.18632/oncotarget.26131. eCollection 2018 Sep 21.

9.

Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.

van de Donk NW, van der Holt B, Minnema MC, Vellenga E, Croockewit S, Kersten MJ, von dem Borne PA, Ypma P, Schaafsma R, de Weerdt O, Klein SK, Delforge M, Levin MD, Bos GM, Jie KG, Sinnige H, Coenen JL, de Waal EG, Zweegman S, Sonneveld P, Lokhorst HM.

Lancet Haematol. 2018 Oct;5(10):e479-e492. doi: 10.1016/S2352-3026(18)30149-2.

PMID:
30290905
10.

CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia.

Naik J, Themeli M, de Jong-Korlaar R, Ruiter RWJ, Poddighe PJ, Yuan H, de Bruijn JD, Ossenkoppele GJ, Zweegman S, Smit L, Mutis T, Martens ACM, van de Donk NWCJ, Groen RWJ.

Haematologica. 2019 Mar;104(3):e100-e103. doi: 10.3324/haematol.2018.192757. Epub 2018 Sep 6. No abstract available.

11.

European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when.

Caers J, Garderet L, Kortüm KM, O'Dwyer ME, van de Donk NWCJ, Binder M, Dold SM, Gay F, Corre J, Beguin Y, Ludwig H, Larocca A, Driessen C, Dimopoulos MA, Boccadoro M, Gramatzki M, Zweegman S, Einsele H, Cavo M, Goldschmidt H, Sonneveld P, Delforge M, Auner HW, Terpos E, Engelhardt M.

Haematologica. 2018 Nov;103(11):1772-1784. doi: 10.3324/haematol.2018.189159. Epub 2018 Aug 31.

12.

The need for information among patients with hematological malignancies: Psychometric analyses of the 62-item Hematology Information Needs Questionnaire (HINQ-62).

Rood JAJ, Lissenberg-Witte BI, Eeltink C, Stam F, van Zuuren FJ, Zweegman S, Verdonck-de Leeuw IM.

PLoS One. 2018 Aug 9;13(8):e0201699. doi: 10.1371/journal.pone.0201699. eCollection 2018.

13.

European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias.

Gavriatopoulou M, Musto P, Caers J, Merlini G, Kastritis E, van de Donk N, Gay F, Hegenbart U, Hajek R, Zweegman S, Bruno B, Straka C, Dimopoulos MA, Einsele H, Boccadoro M, Sonneveld P, Engelhardt M, Terpos E.

Leukemia. 2018 Sep;32(9):1883-1898. doi: 10.1038/s41375-018-0209-7. Epub 2018 Jul 23. Review.

PMID:
30038381
14.

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN).

Larocca A, Dold SM, Zweegman S, Terpos E, Wäsch R, D'Agostino M, Scheubeck S, Goldschmidt H, Gay F, Cavo M, Ludwig H, Straka C, Bringhen S, Auner HW, Caers J, Gramatzki M, Offidani M, Dimopoulos MA, Einsele H, Boccadoro M, Sonneveld P, Engelhardt M.

Leukemia. 2018 Aug;32(8):1697-1712. doi: 10.1038/s41375-018-0142-9. Epub 2018 Apr 25. Review.

15.

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Bladé J, Sonneveld P.

Leukemia. 2018 Jul;32(7):1542-1560. doi: 10.1038/s41375-018-0040-1. Epub 2018 May 2. Review.

16.

Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical Images.

Jauw YWS, Heijtel DF, Zijlstra JM, Hoekstra OS, de Vet HCW, Vugts DJ, Verheul HM, Boellaard R, Zweegman S, van Dongen GAMS, der Houven van Oordt CWM, Lammertsma AA, Huisman MC.

Mol Imaging Biol. 2018 Dec;20(6):1025-1034. doi: 10.1007/s11307-018-1200-4.

17.

RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML.

Cucchi DGJ, Denys B, Kaspers GJL, Janssen JJWM, Ossenkoppele GJ, de Haas V, Zwaan CM, van den Heuvel-Eibrink MM, Philippé J, Csikós T, Kwidama Z, de Moerloose B, de Bont ESJM, Lissenberg-Witte BI, Zweegman S, Verwer F, Vandepoele K, Schuurhuis GJ, Sonneveld E, Cloos J.

Blood. 2018 May 31;131(22):2485-2489. doi: 10.1182/blood-2017-12-819508. Epub 2018 Apr 18.

PMID:
29669779
18.

Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients.

Franssen LE, Nijhof IS, Couto S, Levin MD, Bos GMJ, Broijl A, Klein SK, Ren Y, Wang M, Koene HR, Bloem AC, Beeker A, Faber LM, van der Spek E, Raymakers R, Leguit RJ, Sonneveld P, Zweegman S, Lokhorst H, Mutis T, Thakurta A, Qian X, van de Donk NWCJ.

Haematologica. 2018 Aug;103(8):e368-e371. doi: 10.3324/haematol.2017.186601. Epub 2018 Mar 15. No abstract available.

19.

CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience.

Frerichs KA, Nagy NA, Lindenbergh PL, Bosman P, Marin Soto J, Broekmans M, Groen RWJ, Themeli M, Nieuwenhuis L, Stege C, Nijhof IS, Mutis T, Zweegman S, Lokhorst HM, van de Donk NWCJ.

Expert Rev Clin Immunol. 2018 Mar;14(3):197-206. doi: 10.1080/1744666X.2018.1443809. Epub 2018 Feb 28. Review.

PMID:
29465271
20.

Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma.

van de Donk NWCJ, Casneuf T, Di Cara A, Parren PW, Zweegman S, van Kessel B, Lokhorst HM, Usmani SZ, Lonial S, Richardson PG, Chiu C, Mutis T, Nijhof IS, Sasser AK.

Br J Haematol. 2019 Feb;184(3):475-479. doi: 10.1111/bjh.15122. Epub 2018 Feb 7. No abstract available.

PMID:
29411874
21.

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel.

Caers J, Paiva B, Zamagni E, Leleu X, Bladé J, Kristinsson SY, Touzeau C, Abildgaard N, Terpos E, Heusschen R, Ocio E, Delforge M, Sezer O, Beksac M, Ludwig H, Merlini G, Moreau P, Zweegman S, Engelhardt M, Rosiñol L.

J Hematol Oncol. 2018 Jan 16;11(1):10. doi: 10.1186/s13045-017-0549-1. Review.

22.

Treatment and relative survival in very elderly patients with DLBCL in The Netherlands: a population-based study, 1989 to 2015.

Dinmohamed AG, Issa DE, van der Poel MWM, Schouten HC, Lugtenburg PJ, Chamuleau MED, Zweegman S, Visser O.

Blood Adv. 2017 Sep 22;1(21):1839-1841. doi: 10.1182/bloodadvances.2017011031. eCollection 2017 Sep 26. No abstract available.

23.

A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma.

Cook G, Zweegman S, Mateos MV, Suzan F, Moreau P.

Crit Rev Oncol Hematol. 2018 Jan;121:74-89. doi: 10.1016/j.critrevonc.2017.11.016. Epub 2017 Dec 5. Review.

24.

Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network.

Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Sonneveld P.

Leukemia. 2017 Dec 18. doi: 10.1038/leu.2017.353. [Epub ahead of print] Review.

PMID:
29251284
25.

Health-care professionals' perspective on discussing sexual issues in adult patients after haematopoietic cell transplantation.

Eeltink CM, Witte BI, Stringer J, Liptrott S, Babic A, Greenfield DM, Salooja N, Incrocci L, Visser O, Verdonck-de Leeuw IM, Duarte RF, Zweegman S.

Bone Marrow Transplant. 2018 Mar;53(3):235-245. doi: 10.1038/s41409-017-0027-y. Epub 2017 Dec 15.

PMID:
29247220
26.

Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.

Nijhof IS, van de Donk NWCJ, Zweegman S, Lokhorst HM.

Drugs. 2018 Jan;78(1):19-37. doi: 10.1007/s40265-017-0841-y. Review.

27.

Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.

Scotch AH, Kosiorek H, Scherber R, Dueck AC, Slot S, Zweegman S, Boekhorst PAWT, Commandeur S, Schouten H, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA, Geyer HL.

Leuk Res. 2017 Dec;63:34-40. doi: 10.1016/j.leukres.2017.10.002. Epub 2017 Oct 14.

PMID:
29096334
28.

(Immuno)proteasomes as therapeutic target in acute leukemia.

Cloos J, Roeten MS, Franke NE, van Meerloo J, Zweegman S, Kaspers GJ, Jansen G.

Cancer Metastasis Rev. 2017 Dec;36(4):599-615. doi: 10.1007/s10555-017-9699-4. Review.

29.

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.

Krejcik J, Frerichs KA, Nijhof IS, van Kessel B, van Velzen JF, Bloem AC, Broekmans MEC, Zweegman S, van Meerloo J, Musters RJP, Poddighe PJ, Groen RWJ, Chiu C, Plesner T, Lokhorst HM, Sasser AK, Mutis T, van de Donk NWCJ.

Clin Cancer Res. 2017 Dec 15;23(24):7498-7511. doi: 10.1158/1078-0432.CCR-17-2027. Epub 2017 Oct 12.

30.

Bortezomib resistance in multiple myeloma is associated with increased serine synthesis.

Zaal EA, Wu W, Jansen G, Zweegman S, Cloos J, Berkers CR.

Cancer Metab. 2017 Aug 29;5:7. doi: 10.1186/s40170-017-0169-9. eCollection 2017.

31.

Elderly patients with multiple myeloma: towards a frailty approach?

Zweegman S, Engelhardt M, Larocca A; EHA SWG on ‘Aging and Hematology’.

Curr Opin Oncol. 2017 Sep;29(5):315-321. doi: 10.1097/CCO.0000000000000395. Review.

32.

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.

Goldschmidt H, Lokhorst HM, Mai EK, van der Holt B, Blau IW, Zweegman S, Weisel KC, Vellenga E, Pfreundschuh M, Kersten MJ, Scheid C, Croockewit S, Raymakers R, Hose D, Potamianou A, Jauch A, Hillengass J, Stevens-Kroef M, Raab MS, Broijl A, Lindemann HW, Bos GMJ, Brossart P, van Marwijk Kooy M, Ypma P, Duehrsen U, Schaafsma RM, Bertsch U, Hielscher T, Jarari L, Salwender HJ, Sonneveld P.

Leukemia. 2018 Feb;32(2):383-390. doi: 10.1038/leu.2017.211. Epub 2017 Jul 4.

PMID:
28761118
33.

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.

Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, Jourdan E, Winton E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Lager J, Shun Z, Mesa RA.

Lancet Haematol. 2017 Jul;4(7):e317-e324. doi: 10.1016/S2352-3026(17)30088-1. Epub 2017 Jun 8.

PMID:
28602585
34.

A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization.

Drent E, Themeli M, Poels R, de Jong-Korlaar R, Yuan H, de Bruijn J, Martens ACM, Zweegman S, van de Donk NWCJ, Groen RWJ, Lokhorst HM, Mutis T.

Mol Ther. 2017 Aug 2;25(8):1946-1958. doi: 10.1016/j.ymthe.2017.04.024. Epub 2017 May 13.

35.

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H, Zweegman S, Facon T, Cavo M, Terpos E, Goldschmidt H, Attal M, Buske C; ESMO Guidelines Committee.

Ann Oncol. 2017 Jul 1;28(suppl_4):iv52-iv61. doi: 10.1093/annonc/mdx096. No abstract available.

PMID:
28453614
36.

Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group.

Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, San-Miguel J, Kumar SK, Richardson PG, Mikhael JR, da Costa FL, Dimopoulos MA, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BGM, Zamagni E.

Lancet Oncol. 2017 Apr;18(4):e206-e217. doi: 10.1016/S1470-2045(17)30189-4. Review.

PMID:
28368259
37.

Shared decision-making and providing information among newly diagnosed patients with hematological malignancies and their informal caregivers: Not "one-size-fits-all".

Rood JAJ, Nauta IH, Witte BI, Stam F, van Zuuren FJ, Manenschijn A, Huijgens PC, Verdonck-de Leeuw IM, Zweegman S.

Psychooncology. 2017 Dec;26(12):2040-2047. doi: 10.1002/pon.4414. Epub 2017 Apr 17.

PMID:
28264148
38.

Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.

Jauw YW, Zijlstra JM, de Jong D, Vugts DJ, Zweegman S, Hoekstra OS, van Dongen GA, Huisman MC.

PLoS One. 2017 Jan 6;12(1):e0169828. doi: 10.1371/journal.pone.0169828. eCollection 2017.

39.

A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma.

Franken B, van de Donk NW, Cloos JC, Zweegman S, Lokhorst HM.

Ther Adv Hematol. 2016 Dec;7(6):330-344. Epub 2016 Sep 13. Review.

40.

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.

Nijhof IS, Franssen LE, Levin MD, Bos GMJ, Broijl A, Klein SK, Koene HR, Bloem AC, Beeker A, Faber LM, van der Spek E, Ypma PF, Raymakers R, van Spronsen DJ, Westerweel PE, Oostvogels R, van Velzen J, van Kessel B, Mutis T, Sonneveld P, Zweegman S, Lokhorst HM, van de Donk NWCJ.

Blood. 2016 Nov 10;128(19):2297-2306. doi: 10.1182/blood-2016-07-729236. Epub 2016 Sep 19.

41.

Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy.

Niewerth D, Kaspers GJ, Jansen G, van Meerloo J, Zweegman S, Jenkins G, Whitlock JA, Hunger SP, Lu X, Alonzo TA, van de Ven PM, Horton TM, Cloos J.

J Hematol Oncol. 2016 Sep 6;9(1):82. doi: 10.1186/s13045-016-0312-z.

42.

Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.

Franke NE, Kaspers GL, Assaraf YG, van Meerloo J, Niewerth D, Kessler FL, Poddighe PJ, Kole J, Smeets SJ, Ylstra B, Bi C, Chng WJ, Horton TM, Menezes RX, Musters RJ, Zweegman S, Jansen G, Cloos J.

Oncotarget. 2016 Nov 15;7(46):74779-74796. doi: 10.18632/oncotarget.11340.

43.

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.

Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA.

Haematologica. 2017 Jan;102(1):85-93. doi: 10.3324/haematol.2016.149559. Epub 2016 Aug 18.

44.

Generation and characterization of CD1d-specific single-domain antibodies with distinct functional features.

Lameris R, de Bruin RC, van Bergen En Henegouwen PM, Verheul HM, Zweegman S, de Gruijl TD, van der Vliet HJ.

Immunology. 2016 Sep;149(1):111-21. doi: 10.1111/imm.12635.

45.

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.

Nijhof IS, Casneuf T, van Velzen J, van Kessel B, Axel AE, Syed K, Groen RW, van Duin M, Sonneveld P, Minnema MC, Zweegman S, Chiu C, Bloem AC, Mutis T, Lokhorst HM, Sasser AK, van de Donk NW.

Blood. 2016 Aug 18;128(7):959-70. doi: 10.1182/blood-2016-03-703439. Epub 2016 Jun 15.

46.

(18)F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma.

Regelink JC, Raijmakers PG, Bravenboer N, Milek R, Hoetjes NJ, de Kreuk AM, van Duin M, Wondergem MJ, Lips P, Sonneveld P, Zijlstra JM, Zweegman S.

EJNMMI Res. 2016 Dec;6(1):46. doi: 10.1186/s13550-016-0197-4. Epub 2016 May 31.

47.

Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.

Moreau P, van de Donk NW, Miguel JS, Lokhorst H, Nahi H, Ben-Yehuda D, Cavo M, Cook G, Delforge M, Einsele H, Zweegman S, Ludwig H, Driessen C, Palumbo A, Facon T, Plesner T, Dimopoulos M, Sondergeld P, Sonneveld P, Mateos MV.

Drugs. 2016 Jun;76(9):989-990. No abstract available.

PMID:
27206917
48.

Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.

Alvarez-Larrán A, Pereira A, Guglielmelli P, Hernández-Boluda JC, Arellano-Rodrigo E, Ferrer-Marín F, Samah A, Griesshammer M, Kerguelen A, Andreasson B, Burgaleta C, Schwarz J, García-Gutiérrez V, Ayala R, Barba P, Gómez-Casares MT, Paoli C, Drexler B, Zweegman S, McMullin MF, Samuelsson J, Harrison C, Cervantes F, Vannucchi AM, Besses C.

Haematologica. 2016 Aug;101(8):926-31. doi: 10.3324/haematol.2016.146654. Epub 2016 May 12.

49.

Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

van de Donk NW, Mutis T, Poddighe PJ, Lokhorst HM, Zweegman S.

Int J Lab Hematol. 2016 May;38 Suppl 1:110-22. doi: 10.1111/ijlh.12504. Epub 2016 May 9. Review.

PMID:
27161311
50.

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.

Moreau P, van de Donk NW, San Miguel J, Lokhorst H, Nahi H, Ben-Yehuda D, Cavo M, Cook G, Delforge M, Einsele H, Zweegman S, Ludwig H, Driessen C, Palumbo A, Facon T, Plesner T, Dimopoulos M, Sondergeld P, Sonneveld P, Mateos MV.

Drugs. 2016 May;76(8):853-67. doi: 10.1007/s40265-016-0573-4. Review. Erratum in: Drugs. 2016 Jun;76(9):989-90.

PMID:
27113582

Supplemental Content

Loading ...
Support Center